# A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

> **NCT03740529** · PHASE1,PHASE2 · COMPLETED · sponsor: **Loxo Oncology, Inc.** · enrollment: 803 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Waldenstrom Macroglobulinemia
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- B-cell Lymphoma
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Pirtobrutinib
- **DRUG:** Venetoclax
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03740529
- **Lead sponsor:** Loxo Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-15
- **Primary completion:** 2025-01-27
- **Final completion:** 2025-12-23
- **Target enrollment:** 803 (ACTUAL)
- **Last updated:** 2026-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03740529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03740529, "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03740529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*